Harbour BioMed Company Profile

16:12 EDT 18th August 2018 | BioPortfolio

Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for cancer, with a focus on immuno-oncology, and immunological diseases. The company's discovery and development programs are built around its two patented transgenic mouse platforms (Harbour Mice) for human antibody discovery. The company is building its proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. For additional information, please visit

News Articles [90 Associated News Articles listed on BioPortfolio]

Harbour BioMed Collaborates with WuXi Biologic for Supply of Novel Antibody

Harbour BioMed has formed an "initial strategic" collaboration with WuXi Biologics to develop clinical trial supplies of Harbour's leading HCAb antibody. Harbour, headquartered in the Boston area with...

Harbour BioMed gets rights to Glenmark's bispecific antibody

Glenmark Pharmaceuticals SA granted Harbour BioMed exclusive rights to develop and sell its bispecific antibody GBR1302 for solid tumors in Greater China. Harbour BioMed also retains a manufacturing o...

Glenmark partners Harbour BioMed to develop oncology candidate in China

Glenmark Pharmaceuticals has signed an exclusive licence agreement with Harbour BioMed for the development, manufacture and commercialisation of its immuno-oncology...Read More... The post Glenmark pa...

WuXi Biologics reveals first HCAb partnership alongside Harbour BioMed

WuXi Biologics has announced it will undertake its first collaborative project to develop and manufacture âheavy chain onlyâ antibodies, through an agreement with Harbour BioMed.

Harbour BioMed Teams Up with Wistar to Discover Novel mAbs

Harbour BioMed formed a strategic collaboration with Philadelphia's Wistar Institute to co-discover novel antibodies for cancer and infectious disease indications. The agreement combines Harbour BioMe...

China's Harbour BioMed Mulls Global Licensing

The Shanghai-based biotech startup Harbour Biomed hopes overseas licensing will propel it towards an initial offering in the US, following in...   

WuXi, Harbour BioMed form development and manufacturing collaboration

WuXi Biologics and Harbour BioMed have entered into collaboration for the development and manufacturing of the former’s HCAb antibody.

WuXi Biologics, Harbour BioMed in Strategic Mfg. Alliance

WuXi to support the supply of Harbour's products for clinical trials under IND applications

Drugs and Medications [0 Results]


PubMed Articles [64 Associated PubMed Articles listed on BioPortfolio]

Settling fluxes and ecotoxicological risk assessment of fine sedimentary metals in Tema Harbour (Ghana).

Sediment traps were deployed in the Tema Harbour to estimate the settling fluxes of silt-clay particles and associated metals (Fe, Mn, Pb, Cr, Cu, Zn, Ni, Hg, Sn and As) and characterise their potenti...

Mitochondrial DNA reveals secondary contact in Japanese harbour seals, the southernmost population in the western Pacific.

In this study, we used relatively large number of samples (n = 178) and control region of mtDNA (454bp) to clearify the divergence history of Japanese harbour seals (Phoca vitulina stejnegeri) and phy...

Plastic ingestion by harbour porpoises Phocoena phocoena in the Netherlands: Establishing a standardised method.

Stomach contents of harbour porpoises (Phocoena phocoena) collected in the Netherlands between 2003 and 2013 were inspected for the presence of plastic and other man-made litter. In 654 stomach sample...

Recovery of the New Zealand muricid dogwhelk Haustrum scobina from TBT-induced imposex.

Levels of imposex in the muricid dogwhelk Haustrum scobina (Quoy & Gaimard, 1833) were assessed in two major New Zealand ports between 2015 and 2017, 12+years after the banning of TBT-based antifoulin...

Corrigendum to "double sword role of EZH2 in leukemia" Biomed. Pharmacother. 98 (2018) 626-635.

Clinical Trials [20 Associated Clinical Trials listed on BioPortfolio]

Amendment of rTSST-1 Variant Vaccine Phase 1 First-in-man Trail

Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen to...

Reproducibility of Malaria Challenge in Healthy Volunteers

This is a prospective, single arm, single intervention safety and immunogenicity study in 6 healthy, malaria-naive adults, conducted to demonstrate the successful implementation of the wel...

Endoscopic Resection of Gastric Subepithelial Masses, EndoResect Study

Gastric subepithelial masses might harbour gastrointestinal stromal tumors, which should get resected because of their malignant potential. To minimize the associated surgical trauma endos...

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

We hypothesize that all human malignancies harbour a subpopulation of tumor initiating cells/cancer stem cells (CSCs) that drives tumor development and potentially recurrence or metastasis...

Single-arm Trial of BIBW 2992 in Demographically and Genotypically Selected NSCLC Patients

The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST crit...

Companies [55 Associated Companies listed on BioPortfolio]

Harbour BioMed

Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for cancer, with a focus on immuno-oncology, and immunological diseases. Th...

Biomed Pharmaceuticals

The Company is a leading pharmacy provider of intravenous and injectable medications for patients with chronic disorders. Biomed treats a variety of immune deficient and autoimmun...

BioMed Central Ltd

BioMed Central is an independent publishing house committed to providing immediate open access to peer-reviewed biomedical researchAll original research articles published by BioMed Central are made f...

Harbour Point Capital

Harbour Point Capital (“HPC”) is an independent private equity firm specializing in healthcare investing. The co-founders of HPC have worked together for eight years ...


Biomed AG wurde 1951 in Zürich gegründet und hat sich seither als Handelsunternehmen für pharmazeutische Produkte im Schweizer Markt etabliert. Biomed ist spezialisiert auf den Handel mit rezeptpfl...

More Information about "Harbour BioMed" on BioPortfolio

We have published hundreds of Harbour BioMed news stories on BioPortfolio along with dozens of Harbour BioMed Clinical Trials and PubMed Articles about Harbour BioMed for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Harbour BioMed Companies in our database. You can also find out about relevant Harbour BioMed Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record